Fountain Nathan B 4

What Happened Nathan B. Fountain, a director of Acumen Pharmaceuticals, sold 6,400 shares in an open-market transaction on June 9, 2026. The reported weighted-average sale price was $2.23, producing proceeds of approximately $14,273. This was a sale (code S), which is commonly routine liquidity rather than a direct signal of company prospects.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely filing).
• Shares sold: 6,400; weighted-average price reported: $2.23; total proceeds ≈ $14,273.
• Price range: sales occurred at prices between $2.2300 and $2.2311 (footnote F1). The reporting person can provide a per-trade breakdown to the SEC, the issuer, or any security holder upon request.
• Shares owned after the transaction: not disclosed in this filing.
• Transaction code: S (Sale). No 10b5-1 plan, tax withholding, gift, or option exercise noted in this filing.

Context Sales by corporate insiders can be for many reasons (liquidity, diversification, etc.); this filing is factual and does not indicate motive. The dollar amount is relatively small for an insider sale, and the filing was submitted the next day, so there is no late-reporting flag on this Form 4.